ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 25.04

+0.9%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (372)	12/18/2006 4:15:57 PM
From: NeuroInvestment	Read Replies (1) of 588

Rick: Tuck had PM'd me on this: I am going to look into this a bit more, but this is what I sent as a reply: <<This certainly does point to potential problems with ACP-104 as a monotherapy, which is how Acadia has positioned it--and is running the PhII. I'm not a big fan of these preclinical models of schizophrenia--but to diverge from what is shown by other antipsychotics in terms of putative effects on these target behaviors, and on fos levels in the nucleus accumbens-- certainly makes me think it is unlikely to work as a monotherapy. And if its only advantage is muscarinic activation possibly improving cognitive sx of sz--there will probably be easier ways of getting there (i.e. nicotinic agonists or AMPA modulators). Acadia certainly ran these same animal models--one would have to wonder, assuming their data were similar, why they'd have developed ACP-104 as monotherapy....With ACP-103, that makes two adjuncts....they may have fallen in love with the Clozapine Junior aspect, but this indicates that the apple sometimes does fall far from the tree.... Enjoy the holidays.... Harry NeuroInvestment>>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next